Patents for A61P 35 - Antineoplastic agents (221,099)
02/2010
02/24/2010EP1007084B1 Immunogenic lhrh compositions and methods relating thereto
02/24/2010EP0861261B9 Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
02/24/2010EP0837696B1 Improved delivery of diagnostic and therapeutic agents to a target site
02/24/2010CN101654673A Rna interference mediating small rna molecules
02/24/2010CN101654672A Rna interference mediating small rna molecules
02/24/2010CN101654479A Mammalian receptor proteins, agents, and methods relating thereto
02/24/2010CN101653603A Peptides and antibodies binding to anionic phospholipids and aminophospholipids and their use in treating disease
02/24/2010CN101653594A Somatostatin-dopamine chimeric analogs
02/24/2010CN101653424A 高药物载荷片剂 High drug load tablets
02/24/2010CN101653354A Noninvasive measurements of chemical substances
02/24/2010CN100591762C Antigen presenting cells, method for their preparation and their use for cancer vaccines
02/24/2010CN100591760C Process for producing cytotoxic lymphocyte
02/24/2010CN100591691C Anti-tumour compound
02/24/2010CN100591689C Solid salts of benzazepine compounds and its uses in preparing pharmaceutical compound containing them
02/24/2010CN100591355C Compositions for treating hyperproliferative conditions and its pharmaceutical uses
02/24/2010CN100591331C Combination chemotherapy compositions
02/23/2010USRE41151 Comprising a modified NSAID, wherein the NSAID is covalently attached either directly or through a linker molecule to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety; nonsteroidal anti-inflammatory drugs; side-effect reduction
02/23/2010USRE41150 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one
02/23/2010US7668659 Diagnosis and classification of multiple myeloma
02/23/2010US7667052 Bioactive substance
02/23/2010US7667036 Pyrazolo[1,5-a]pyrimidine derivatives
02/23/2010US7667027 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-β (TGF-β)
02/23/2010US7667021 Neutralizing human anti-IGFR antibody
02/23/2010US7667015 Genetic engineering; induce immunology response; biodrug as anticarcinogenic agents, for pancreatic cancer
02/23/2010US7667013 Gene encoding a guanine nucleotide exchange factor and the gene product thereof
02/23/2010US7667008 Heparin binding protein for use in controlling angiogenesis and as wound healing agent
02/23/2010US7667007 αvβ3-specific antibodies
02/23/2010US7667002 Peptides and proteins for early liver development and antibodies thereto
02/23/2010US7666999 Neutral amino acid transporter and gene thereof
02/23/2010US7666998 Cell growth inhibitor containing anti-PepT antibody
02/23/2010US7666995 Interferons, uses and compositions related thereto
02/23/2010US7666985 HLA-A24-restricted cancer antigen peptides
02/23/2010US7666983 peptides that activate the DNA binding activity of the wild-type form of the p53 tumor suppressor, as well as of certain tumor-derived p53 mutants
02/23/2010US7666905 Compositions comprising hepoxilin analogs and their use in the treatment of cancer
02/23/2010US7666897 Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
02/23/2010US7666892 N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}-4-(4-fluorophenoxy)benzenesulfonamide and N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}[1,1'-biphenyl]-4-sulfonamide; chemical intermediates for enzyme inhibitors; especially as inhibitors of MMP12
02/23/2010US7666885 Enzyme inhibitors
02/23/2010US7666874 hypereosinophilic syndrome with resistance to imatinib
02/23/2010US7666873 N-phenyl-(2R,5S)dimethylpiperazine derivative
02/23/2010US7666862 2,4-Diphenyl-1-(hexamethylenimin-4-ylaminocarbonyl)dihydropyrrole derivatives that are useful for treating cancer
02/23/2010US7666848 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics
02/23/2010US7666839 Methods of treatment using specific binding agents of human angiopoietin-2
02/23/2010US7666832 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent
02/23/2010US7666831 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent
02/23/2010US7666639 Plant deoxyribonucleoside kinase enzymes and their use
02/23/2010US7666624 Chemically conjugating a peptide of interest to a heterologous peptide that has been expressed on the coat protein of a cowpea mosaic virus to generate a conjugate and administering the conjugate to a host animal to increase the level of TH1-type immune response
02/23/2010US7666604 Modified soluble T cell receptor
02/23/2010US7666581 Complexing antigenic proteins/peptides; membrane proteins; tumor associated antigens
02/23/2010US7666430 Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
02/23/2010US7666426 Method for immune response eliciting in a mammal
02/23/2010US7666425 Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen
02/23/2010US7666422 Methods for the treatment of cancer using anti-CD40 antibodies
02/23/2010US7666401 Compositions comprising a ligand of Chemerin R
02/23/2010CA2442974C Use of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of cell proliferation diseases
02/23/2010CA2433021C Isoindole-imide compounds, compositions, and uses thereof
02/23/2010CA2403566C Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
02/23/2010CA2355834C Human akt-3
02/23/2010CA2315277C Pharmaceutical compositions containing the long pentraxin ptx3
02/18/2010WO2010019954A2 Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs
02/18/2010WO2010019899A1 cMET INHIBITORS
02/18/2010WO2010019864A2 Ficus extracts having angiogenesis inhibiting activity and methods of isolating and using the same
02/18/2010WO2010019775A2 Methods of treating ras driven cancer in a subject
02/18/2010WO2010019701A2 Diaryl urea derivatives
02/18/2010WO2010019659A1 Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use
02/18/2010WO2010019549A2 Indoprofen derivatives for promoting bone growth
02/18/2010WO2010019473A1 Aurora kinase modulators and methods of use
02/18/2010WO2010019276A2 Method and formulation for treating adverse biological conditions
02/18/2010WO2010019257A2 Prodrug activation in cancer cells using molecular switches
02/18/2010WO2010019233A1 Multi-arm polymeric alkanoate conjugates
02/18/2010WO2010019210A2 Halofuginone analogs for inhibition of trna synthetases and uses thereof
02/18/2010WO2010019120A1 S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma
02/18/2010WO2010019103A1 The use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer
02/18/2010WO2010018846A1 Drug containing antibody composition specifically binding to ganglioside gm2
02/18/2010WO2010018764A1 Anti-angiogenic agent, and screening method and screening kit for same
02/18/2010WO2010018481A1 2-amino pyrimidine compounds as potent hsp-90 inhibitors
02/18/2010WO2010018327A1 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-ib]-pyridazine derivatives, preparation thereof, and therapeutic application thereof
02/18/2010WO2010018268A1 Novel (rs)-7- or 9-(1,2,3,5-tetrahydro-4,1-benzoxazepin-3-il)-7h or 9h-purines having antitumour activity
02/18/2010WO2010018223A1 Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsions
02/18/2010WO2010018217A2 Organic compounds for wound healing
02/18/2010WO2010018207A1 Endoglin peptides, vaccines and methods for preparing the same
02/18/2010WO2010018182A1 Peptidic and peptidomimetic compounds for regulating autophagy
02/18/2010WO2010018133A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
02/18/2010WO2010018132A1 Compounds
02/18/2010WO2010018131A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
02/18/2010WO2010018130A1 Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
02/18/2010WO2010017870A1 Bicyclic triazole derivatives for treating tumors
02/18/2010WO2010017827A1 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
02/18/2010WO2010017743A1 The injectable sustained-release formulation of lhrh antagonists and the preparation thereof
02/18/2010WO2010017598A1 Anti-il-12/il-23 antibodies
02/18/2010WO2010017587A1 Novel protease inhibitors
02/18/2010WO2009155121A3 Inhibitors of pi3 kinase
02/18/2010WO2009150381A3 Azacarboline derivatives, preparation thereof, and therapeutic use thereof as kinase inhibitors
02/18/2010WO2009146099A3 Contrast agents, methods for preparing contrast agents, and methods of imaging
02/18/2010WO2009144738A4 Medicinal applications of benzoic acid hydrazones synthesized on the basis of steroidal tigogenin
02/18/2010WO2009139972A3 Site specific fluorescence marking and contrast marker for same
02/18/2010WO2009139891A3 Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
02/18/2010WO2009135000A3 Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
02/18/2010WO2009134962A3 Claudin-4 binding peptides, compositions and methods of use
02/18/2010WO2009129260A3 Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
02/18/2010WO2009126705A3 Induction of tumor hypoxia for cancer therapy